Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 15;10(9):2426.
doi: 10.3390/cells10092426.

Role of Complement in Regulating Inflammation Processes in Renal and Prostate Cancers

Giuseppe Stefano Netti  1 , Rossana Franzin  2 , Alessandra Stasi  2 , Federica Spadaccino  1 , Andrea Dello Strologo  3 , Barbara Infante  3 , Loreto Gesualdo  2 , Giuseppe Castellano  3 , Elena Ranieri  1 , Giovanni Stallone  3
Affiliations
Review

Role of Complement in Regulating Inflammation Processes in Renal and Prostate Cancers

Giuseppe Stefano Netti et al. Cells. .

Abstract

For decades, the complement system, the central pillar of innate immune response, was recognized as a protective mechanism against cancer cells and the manipulation of complement effector functions in cancer setting offered a great opportunity to improve monoclonal antibody-based cancer immunotherapies. Similarly, cellular senescence, the process of cell cycle arrest that allow DNA and tissue repair has been traditionally thought to be able to suppress tumor progression. However, in recent years, extensive research has identified the complement system and cellular senescence as two main inducers of tumour growth in the context of chronic, persistent inflammation named inflammaging. Here, we discuss the data describing the ambivalent role of senescence in cancer with a particular focus on tumors that are strongly dependent on complement activation and can be understood by a new, senescence-related point of view: prostate cancer and renal cell carcinoma.

Keywords: PTX3; SASP; cellular senescence; complement system; inflammaging; prostate cancer; renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 2001;344:1058–1066. doi: 10.1056/NEJM200104053441406. - DOI - PubMed
    1. Walport M.J. Complement. Second of two parts. N. Engl. J. Med. 2001;344:1140–1144. doi: 10.1056/NEJM200104123441506. - DOI - PubMed
    1. Roumenina L.T., Daugan M.V., Petitprez F., Sautès-Fridman C., Fridman W.H. Context-dependent roles of complement in cancer. Nat. Rev. Cancer. 2019;19:698–715. doi: 10.1038/s41568-019-0210-0. - DOI - PubMed
    1. Ricklin D., Reis E.S., Lambris J.D. Complement in disease: A defence system turning offensive. Nat. Rev. Nephrol. 2016;12:383–401. doi: 10.1038/nrneph.2016.70. - DOI - PMC - PubMed
    1. Reis E.S., Mastellos D.C., Ricklin D., Mantovani A., Lambris J.D. Complement in cancer: Untangling an intricate relationship. Nat. Rev. Immunol. 2018;18:5–18. doi: 10.1038/nri.2017.97. - DOI - PMC - PubMed

Publication types